atopic dermatitis

News

RAPT hit by FDA clinical hold on eczema, asthma drug

RAPT Therapeutics has seen its shares fall sharply after the FDA placed a clinical hold on oral CCR4 antagonist zelnecirnon, currently in a phase 2b trial for atopic derma

News

LEO says chronic hand eczema drug bests its only rival

Dermatology specialist LEO Pharma has built the case for its first-in-class chronic hand eczema (CHE) drug delgocitinib, saying it outperformed the only approved drug ther

News

After FDA no, Almirall’s eczema drug gets EU okay

The European Commission has approved Almirall’s lebrikizumab as Ebglyss for the treatment of moderate-to-severe atopic dermatitis (AD), with an EU rollout set to start in

News

FDA turns down Lilly’s eczema drug lebrikizumab

Problems at a contract manufacturing organisation have scuppered Eli Lilly’s hopes of a timely FDA approval for lebrikizumab, its IL-13 inhibitor for the treatment of atop

News

CHMP backs Almirall’s eczema therapy lebrikizumab

Almirall is within sniffing distance of EU approval for its IL-13 inhibitor lebrikizumab for atopic dermatitis, setting up a challenge to Sanofi and Regeneron’s market-lea

News

Nektar says Lilly got it wrong on eczema drug rezpeg

Nektar Therapeutics says that Eli Lilly made a big mistake when it reported data on a pair of phase 1b trials of its rezpegaldesleukin drug in atopic dermatitis and psoria

RAPT hit by FDA clinical hold on eczema, asthma drug

LEO says chronic hand eczema drug bests its only rival

After FDA no, Almirall’s eczema drug gets EU okay

FDA turns down Lilly’s eczema drug lebrikizumab

CHMP backs Almirall’s eczema therapy lebrikizumab

Nektar says Lilly got it wrong on eczema drug rezpeg

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

atopic dermatitis

Editor's Picks